Acura Pharmaceuticals Announces Return of Product Rights from Pfizer

Acura Pharmaceuticals ACUR announced today a letter agreement with Pfizer Inc. providing for the termination of Pfizer's PFE license to Acura's AVERSION Technology and the return to Acura of the FDA approved Oxecta product. The letter agreement provides that Acura will make a one-time payment of $2.0 million to Pfizer. The license termination is effective April 9, 2014. The AVERSION Technology utilizes a proprietary mixture of inactive ingredients to discourage tampering of a product for abusive purposes.